GlassScriptPhysician profile
Charles A Pastor
NPI 1871617316
$15,702.31
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,178 · 2020: $8,795 · 2021: $1,552 · 2023: $156 · 2024: $22.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,852.94 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,096.54 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $717.75 | 2019-2021 | |
| Gilead Sciences, INC. | $644.40 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $594.03 | 2019-2021 | |
| Allergan, INC. | $406.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $328.77 | 2019-2020 | |
| Pfizer INC. | $324.34 | 2019-2021 | |
| Viiv Healthcare Company | $304.28 | 2019-2021 | |
| Glaxosmithkline, LLC. | $241.51 | 2019-2021 | |
| Smith+Nephew, INC. | $164.69 | 2020 | |
| Daiichi Sankyo INC. | $156.26 | 2019-2020 | |
| Janssen Biotech, INC. | $155.98 | 2020-2021 | |
| Horizon Therapeutics Plc | $116.35 | 2019-2020 | |
| Stryker Corporation | $108.57 | 2023 | Surpass Evolve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $89.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.84 | 2019-2021 | |
| Amgen INC. | $57.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $51.17 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.12 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.69 | 2019-2021 | |
| Redhill Biopharma INC. | $39.84 | 2020-2021 | |
| Amarin Pharma, INC. | $30.35 | 2019 | |
| Novo Nordisk INC | $19.04 | 2019 | |
| Shionogi INC | $12.60 | 2019 | |
| Alkermes, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Pastor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.